Distinction of primary ovarian mucinous tumors and mucinous tumors metastatic to the ovary: A practical approach with guidelines for prediction of primary site for metastases of uncertain origin

Pathology Case Reviews

Volumn 11, Issue 1, 2006, Pages 18-30

  Vang, Russell ^a,b   Ronnett, Brigitte M ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

Atypical proliferative (borderline) mucinous tumor; Immunohistochemistry; Metastatic carcinoma; Ovary; Primary mucinous carcinoma

Indexed keywords

CYTOKERATIN 20; CYTOKERATIN 7; PROTEIN P16; SMAD4 PROTEIN; TUMOR MARKER;

ADENOCARCINOMA; ADULT; APPENDIX TUMOR; BILE DUCT CARCINOMA; CASE REPORT; CELL ULTRASTRUCTURE; CLINICAL FEATURE; COLORECTAL CARCINOMA; CONSULTATION; CURETTAGE; DIAGNOSTIC ACCURACY; DIFFERENTIAL DIAGNOSIS; EVALUATION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; LAPAROSCOPIC SURGERY; LYMPH NODE DISSECTION; MUCINOUS CARCINOMA; OVARIAN MUCINOUS TUMOR; OVARY CYST; OVARY METASTASIS; PANCREAS ADENOCARCINOMA; PARAAORTIC LYMPH NODE; PELVIS LYMPH NODE; PEROPERATIVE CARE; PRACTICE GUIDELINE; PREDICTION; PRIORITY JOURNAL; REVIEW; SALPINGOOOPHORECTOMY; STOMACH ADENOCARCINOMA; SYMPTOM; UTERINE CERVIX CARCINOMA;

EID: 33746622114     PISSN: 10829784     EISSN: 15334015     Source Type: Journal    
DOI: 10.1097/01.pcr.0000196570.96459.9e     Document Type: Review

References (72)

1. Mazur MT, Hsueh S, Gersell DJ. Metastases to the female genital tract: analysis of 325 cases. Cancer. 1984;53:1978-1984.
2. Moore RG, Chung M, Granai CO, et al. Incidence of metastasis to the ovaries from nongenital tract primary tumors. Gynecol Oncol. 2004;93:87-91.
3. Ulbright TM, Roth LM, Stehman FB. Secondary ovarian neoplasia: a clinicopathologic study of 35 cases. Cancer. 1984;53:1164-1174.
4. Yazigi R, Sandstad J. Ovarian involvement in extragenital cancer. Gynecol Oncol. 1989;34:84-87.
5. Lee KR, Young RH. The distinction between primary and metastatic mucinous carcinomas of the ovary: gross and histologic findings in 50 cases. Am J Surg Pathol. 2003;27:281-292.
6. Seidman JD, Kurman RJ, Ronnett BM. Primary and metastatic mucinous adenocarcinomas in the ovaries: incidence in routine practice with a new approach to improve intraoperative diagnosis. Am J Surg Pathol. 2003;27:985-993.
7. Berezowski K, Stastny JF, Kornstein MJ. Cytokeratins 7 and 20 and carcinoembryonic antigen in ovarian and colonic carcinoma. Mod Pathol. 1996;9:426-429.
8. Cathro HP, Stoler MH. Expression of cytokeratins 7 and 20 in ovarian neoplasia. Am J Clin Pathol. 2002;117:944-951.
9. Chou YY, Jeng YM, Kao HL, et al. Differentiation of ovarian mucinous carcinoma and metastatic colorectal adenocarcinoma by immunostaining with beta-catenin. Histopathology. 2003;43:151-156.
10. Dionigi A, Facco C, Tibiletti MG, et al. Ovarian metastases from colorectal carcinoma: clinicopathologic profile, immunophenotype, and karyotype analysis. Am J Clin Pathol. 2000;114:111-122.
11. Fowler LJ, Maygarden SJ, Novotny DB. Human alveolar macrophage-56 and carcinoembryonic antigen monoclonal antibodies in the differential diagnosis between primary ovarian and metastatic gastrointestinal carcinomas. Hum Pathol. 1994;25:666-670.
12. Goldstein NS, Bassi D, Uzieblo A. WT1 is an integral component of an antibody panel to distinguish pancreaticobiliary and some ovarian epithelial neoplasms. Am J Clin Pathol. 2001;116:246-252.
13. Hoerl HD, Hart WR. Primary ovarian mucinous cystadenocarcinomas: a clinicopathologic study of 49 cases with long-term follow-up. Am J Surg Pathol. 1998;22:1449-1462.
14. Ji H, Isacson C, Seidman JD, et al. Cytokeratins 7 and 20, Dpc4, and MUC5AC in the distinction of metastatic mucinous carcinomas in the ovary from primary ovarian mucinous tumors: Dpc4 assists in identifying metastatic pancreatic carcinomas. Int J Gynecol Pathol. 2002;21:391-400.
15. Lee KR, Scully RE. Mucinous tumors of the ovary: a clinicopathologic study of 196 borderline tumors (of intestinal type) and carcinomas, including an evaluation of 11 cases with "pseudomyxoma peritonei." Am J Surg Pathol. 2000;24:1447-1464.
16. Multhaupt HA, Arenas-Elliott CP, Warhol MJ. Comparison of glycoprotein expression between ovarian and colon adenocarcinomas. Arch Pathol Lab Med. 1999;123:909-916.
17. Riopel MA, Ronnett BM, Kurman RJ. Evaluation of diagnostic criteria and behavior of ovarian intestinal-type mucinous tumors: atypical proliferative (borderline) tumors and intraepithelial, microinvasive, invasive, and metastatic carcinomas. Am J Surg Pathol. 1999;23:617-635.
18. Rodriguez IM, Prat J. Mucinous tumors of the ovary: a clinicopathologic analysis of 75 borderline tumors (of intestinal type) and carcinomas. Am J Surg Pathol. 2002;26:139-152.
19. Ronnett BM, Kajdacsy-Balla A, Gilks CB, et al. Mucinous borderline ovarian tumors: points of general agreement and persistent controversies regarding nomenclature, diagnostic criteria, and behavior. Hum Pathol. 2004;35:949-960.
20. Ronnett BM, Seidman JD. Mucinous tumors arising in ovarian mature cystic teratomas: relationship to the clinical syndrome of pseudomyxoma peritonei. Am J Surg Pathol. 2003;27:650-657.
21. Seidman JD, Soslow RA, Vang R, et al. Borderline ovarian tumors: diverse contemporary viewpoints on terminology and diagnostic criteria with illustrative images. Hum Pathol. 2004;35:918-933.
22. Vang R, Gown AM, Barry TS, et al. Immunohistochemistry for estrogen and progesterone receptors in the distinction of primary and metastatic mucinous tumors in the ovary: an analysis of 124 cases. Mod Pathol. 2006;19:97-105.
23. Chu P, Wu E, Weiss LM. Cytokeratin 7 and cytokeratin 20 expression in epithelial neoplasms: a survey of 435 cases. Mod Pathol. 2000;13:962-972.
24. Daya D, Nazerali L, Frank GL. Metastatic ovarian carcinoma of large intestinal origin simulating primary ovarian carcinoma: a clinicopathologic study of 25 cases. Am J Clin Pathol. 1992;97:751-758.
25. Judson K, Vang R, Ronnett B. Women with undiagnosed colorectal adenocarcinomas presenting with ovarian metastases: clinicopathologic features and comparison to women with known colorectal adenocarcinoma having ovarian metastases [abstract 872]. Mod Pathol. 2005;18:187A.
26. Lash RH, Hart WR. Intestinal adenocarcinomas metastatic to the ovaries: a clinicopathologic evaluation of 22 cases. Am J Surg Pathol. 1987;11:114-121.
27. Park SY, Kim HS, Hong EK, et al. Expression of cytokeratins 7 and 20 in primary carcinomas of the stomach and colorectum and their value in the differential diagnosis of metastatic carcinomas to the ovary. Hum Pathol. 2002;33:1078-1085.
28. Ronnett B, Gown AM, Barry TS, et al. Utility of immunohistochemistry in determining the site of origin of metastatic mucinous carcinomas involving the ovary [abstract 934]. Mod Pathol. 2005;18:201A.
29. Wang NP, Zee S, Zarbo RJ, et al. Coordinate expression of cytokeratins 7 and 20 defines unique subsets of carcinomas. Appl Immunohistochem. 1995;3:99-107.
30. Young RH, Hart WR. Metastatic intestinal carcinomas simulating primary ovarian clear cell carcinoma and secretory endometrioid carcinoma: a clinicopathologic and immunohistochemical study of five cases. Am J Surg Pathol. 1998;22:805-815.
31. Zhang PJ, Shah M, Spiegel GW, et al. Cytokeratin 7 immunoreactivity in rectal adenocarcinomas. Appl Immunohistochem Mol Morphol. 2003;11:306-310.
32. Duval JV, Savas L, Banner BF. Expression of cytokeratins 7 and 20 in carcinomas of the extrahepatic biliary tract, pancreas, and gallbladder. Arch Pathol Lab Med. 2000;124:1196-1200.
33. Goldstein NS, Bassi D. Cytokeratins 7, 17, and 20 reactivity in pancreatic and ampulla of Vater adenocarcinomas: percentage of positivity and distribution is affected by the cut-point threshold. Am J Clin Pathol. 2001;115:695-702.
34. Kang YK, Kim WH, Jang JJ. Expression of G1-S modulators (p53, p16, p27, cyclin D1, Rb) and Smad4/Dpc4 in intrahepatic cholangiocarcinoma. Hum Pathol. 2002;33:877-883.
35. Kim KH, Kim CD, Lee HS, et al. Bilateral ovarian carcinoma metastatic from the ampulla of Vater: a rare Krukenberg tumor. J Korean Med Sci. 1999;14:220-222.
36. Low JJ, Chew SH, Chew SP, et al. A rare case of metastatic ovarian carcinoma originating from primary intrahepatic cholangiocarcinoma: case report. Eur J Gynaecol Oncol. 2003;24:85-88.
37. McCarthy DM, Hruban RH, Argani P, et al. Role of the DPC4 tumor suppressor gene in adenocarcinoma of the ampulla of Vater: analysis of 140 cases. Mod Pathol. 2003;16:272-278.
38. Rullier A, Le Bail B, Fawaz R, et al. Cytokeratin 7 and 20 expression in cholangiocarcinomas varies along the biliary tract but still differs from that in colorectal carcinoma metastasis. Am J Surg Pathol. 2000;24:870-876.
39. Tang Z, Zou S, Hao Y, et al. Frequency of loss expression of the DPC4 protein in various locations of biliary tract carcinoma. Zhonghua Yu Fang Yi Xue Za Zhi. 2002;36:481-484.
40. Vang R, Gown AM, Barry TS, et al. CDX2 versus CK20 and CK7 for distinction of primary ovarian mucinous tumors from metastatic mucinous carcinomas involving the ovary [abstract 962]. Mod Pathol. 2005;18:207A.
41. Young RH, Hart WR. Metastases from carcinomas of the pancreas simulating primary mucinous tumors of the ovary: a report of seven cases. Am J Surg Pathol. 1989;13:748-756.
42. Young RH, Scully RE. Ovarian metastases from carcinoma of the gallbladder and extrahepatic bile ducts simulating primary tumors of the ovary: a report of six cases. Int J Gynecol Pathol. 1990;9:60-72.
43. Bullon A Jr, Arseneau J, Prat J, et al. Tubular Krukenberg tumor: a problem in histopathologic diagnosis. Am J Surg Pathol. 1981;5:225-232.
44. Chu PG, Weiss LM. Immunohistochemical characterization of signetring cell carcinomas of the stomach, breast, and colon. Am J Clin Pathol. 2004;121:884-892.
45. Goldstein NS, Long A, Kuan SF, et al. Colon signet ring cell adenocarcinoma: immunohistochemical characterization and comparison with gastric and typical colon adenocarcinomas. Appl Immunohistochem Mol Morphol. 2000;8:183-188.
46. Hale RW. Krukenberg tumor of the ovaries: a review of 81 records. Obstet Gynecol. 1968;32:221-225.
47. Holtz F, Hart WR. Krukenberg tumors of the ovary: a clinicopathologic analysis of 27 cases. Cancer. 1982;50:2438-2447.
48. Woodruff JD, Novak ER. The Krukenberg tumor: study of 48 cases from the ovarian tumor registry. Obstet Gynecol. 1960;15:351-360.
49. Yakushiji M, Tazaki T, Nishimura H, et al. Krukenberg tumors of the ovary: a clinicopathologic analysis of 112 cases. Nippon Sanka Fujinka Gakkai Zasshi. 1987;39:479-485.
50. Misdraji J, Yantiss RK, Graeme-Cook FM, et al. Appendiceal mucinous neoplasms: a clinicopathologic analysis of 107 cases. Am J Surg Pathol. 2003;27:1089-1103.
51. Prayson RA, Hart WR, Petras RE. Pseudomyxoma peritonei: a clinicopathologic study of 19 cases with emphasis on site of origin and nature of associated ovarian tumors. Am J Surg Pathol. 1994;18:591-603.
52. Ronnett BM, Kurman RJ, Shmookler BM, et al. The morphologic spectrum of ovarian metastases of appendiceal adenocarcinomas: a clinicopathologic and immunohistochemical analysis of tumors often misinterpreted as primary ovarian tumors or metastatic tumors from other gastrointestinal sites. Am J Surg Pathol. 1997;21:1144-1155.
53. Ronnett BM, Kurman RJ, Zahn CM, et al. Pseudomyxoma peritonei in women: a clinicopathologic analysis of 30 cases with emphasis on site of origin, prognosis, and relationship to ovarian mucinous tumors of low malignant potential. Hum Pathol. 1995;26:509-524.
54. Ronnett BM, Shmookler BM, Diener-West M, et al. Immunohistochemical evidence supporting the appendiceal origin of pseudomyxoma peritonei in women. Int J Gynecol Pathol. 1997;16:1-9.
55. Ronnett BM, Yan H, Kurman RJ, et al. Patients with pseudomyxoma peritonei associated with disseminated peritoneal adenomucinosis have a significantly more favorable prognosis than patients with peritoneal mucinous carcinomatosis. Cancer. 2001;92:85-91.
56. Ronnett BM, Zahn CM, Kurman RJ, et al. Disseminated peritoneal adenomucinosis and peritoneal mucinous carcinomatosis: a clinicopathologic analysis of 109 cases with emphasis on distinguishing pathologic features, site of origin, prognosis, and relationship to "pseudomyxoma peritonei." Am J Surg Pathol. 1995;19:1390-1408.
57. Young RH, Gilks CB, Scully RE. Mucinous tumors of the appendix associated with mucinous tumors of the ovary and pseudomyxoma peritonei: a clinicopathological analysis of 22 cases supporting an origin in the appendix. Am J Surg Pathol. 1991;15:415-429.
58. Anttila M, Syrjanen S, Ji H, et al. Failure to demonstrate human papillomavirus DNA in epithelial ovarian cancer by general primer PCR. Gynecol Oncol. 1999;72:337-341.
59. Elishaev E, Gilks CB, Miller D, et al. Synchronous and metachronous endocervical and ovarian neoplasms: evidence supporting interpretation of the ovarian neoplasms as metastatic endocervical adenocarcinomas simulating primary ovarian surface epithelial neoplasms. Am J Surg Pathol. 2005;29:281-294.
60. Kaminski PF, Norris HJ. Coexistence of ovarian neoplasms and endocervical adenocarcinoma. Obstet Gynecol. 1984;64:553-556.
61. Mikami Y, Kiyokawa T, Moriya T, et al. Immunophenotypic alteration of the stromal component in minimal deviation adenocarcinoma ("adenoma malignum") and endocervical glandular hyperplasia: a study using oestrogen receptor and alpha-smooth muscle actin double immunostaining. Histopathology. 2005;46:130-136.
62. Plaza JA, Ramirez NC, Nuovo GJ. Utility of HPV analysis for evaluation of possible metastatic disease in women with cervical cancer. Int J Gynecol Pathol. 2004;23:7-12.
63. Toki T, Shiozawa T, Hosaka N, et al. Minimal deviation adenocarcinoma of the uterine cervix has abnormal expression of sex steroid receptors, CA125, and gastric mucin. Int J Gynecol Pathol. 1997;16:111-116.
64. Young RH, Scully RE. Mucinous ovarian tumors associated with mucinous adenocarcinomas of the cervix: a clinicopathological analysis of 16 cases. Int J Gynecol Pathol. 1988;7:99-111.
65. An HJ, Kim KR, Kim IS, et al. Prevalence of human papillomavirus DNA in various histological subtypes of cervical adenocarcinoma: a population-based study. Mod Pathol. 2005;18:528-534.
66. Ferguson AW, Svoboda-Newman SM, Frank TS. Analysis of human papillomavirus infection and molecular alterations in adenocarcinoma of the cervix. Mod Pathol. 1998;11:11-18.
67. Pirog EC, Kleter B, Olgac S, et al. Prevalence of human papillomavirus DNA in different histological subtypes of cervical adenocarcinoma. Am J Pathol. 2000;157:1055-1062.
68. Toki T, Zhai YL, Park JS, et al. Infrequent occurrence of high-risk human papillomavirus and of p53 mutation in minimal deviation adenocarcinoma of the cervix. Int J Gynecol Pathol. 1999;18:215-219.
69. Xu JY, Hashi A, Kondo T, et al. Absence of human papillomavirus infection in minimal deviation adenocarcinoma and lobular endocervical glandular hyperplasia. Int J Gynecol Pathol. 2005;24:296-302.
70. Young RH, Scully RE. Metastatic tumors in the ovary: a problem-oriented approach and review of the recent literature. Semin Diagn Pathol. 1991;8:250-276.
71. Vang R, Gown AM, Zhao C, et al. Expression of CK7 and CK20 in ovarian mucinous tumors arising in association with teratomas: a CK7/CK20 subset can cause confusion with metastatic lower gastrointestinal (GI) tract mucinous tumors [abstract]. Mod Pathol. 2006;19:200A.
72. Vang R, Gown AM, Barry TS, et al. P16 expression in primary ovarian mucinous and endometrioid tumors and metastatic adenocarcinomas in the ovary: utility for identification of metastatic HPV-related endocervical adenocarcinomas [abstract]. Mod Pathol. 2006;19:200A.